China National Medicines: Q3 profit rose, but nine-month earnings slipped
China National Medicines grew Q3 revenue and net income, while nine-month profit declined and its operating cash outflow widened, according to TradingView.
- published on Newsmetry
- original source published
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner. connect the api →
what happened
According to TradingView, China National Medicines saw third-quarter revenue increase 0.95% year on year, while attributable net income climbed 9.70%.
For the first nine months, revenue rose 3.11%, but attributable net income fell 1.07%. The operating cash outflow also widened compared with a year earlier.
The source notes that the text is an AI-generated summary and may contain inaccuracies, so key figures should be checked against the original filing.
why it matters
The gap between the quarter and the nine-month period suggests the company's profit recovery is uneven, and a larger operating cash outflow may prompt investors to question the quality of its earnings. For markets, the data is mainly a signal about the health of China's pharmaceutical distribution sector.
market impact
China pharma distribution: weak nine-month cash flow may add caution among investors toward the sector
tags
instruments
sources
- CHINA NATIONAL MEDICINES CORP: Q3 profit grew, but YTD earnings softened and operating cash outflow widened — TradingView, 20 October 2026 at 08:47 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner.
get stories in real time ↗